Multicenter phase II study of Taxotere (docetaxel) administered weekly or every three weeks in combination with prednisone as second line chemotherapy in patients with hormone refractory prostate cancer (HRPC).

Trial Profile

Multicenter phase II study of Taxotere (docetaxel) administered weekly or every three weeks in combination with prednisone as second line chemotherapy in patients with hormone refractory prostate cancer (HRPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jan 2007 Status change
    • 12 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top